<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 receptor (GLP-1R) <z:chebi fb="4" ids="48705">agonists</z:chebi> are used to treat type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, and transient GLP-1 administration improved cardiac function in humans after <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> (MI) and percutaneous revascularization </plain></SENT>
<SENT sid="1" pm="."><plain>However, the consequences of GLP-1R activation before ischemic myocardial injury remain unclear </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: We assessed the pathophysiology and outcome of coronary <z:mp ids='MP_0006134'>artery occlusion</z:mp> in <z:mpath ids='MPATH_458'>normal</z:mpath> and diabetic mice pretreated with the GLP-1R <z:chebi fb="4" ids="48705">agonist</z:chebi> liraglutide </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Male C57BL/6 mice were treated twice daily for 7 days with liraglutide or saline followed by induction of MI </plain></SENT>
<SENT sid="4" pm="."><plain>Survival was significantly higher in liraglutide-treated mice </plain></SENT>
<SENT sid="5" pm="."><plain>Liraglutide reduced <z:e sem="disease" ids="C0018813" disease_type="Disease or Syndrome" abbrv="">cardiac rupture</z:e> (12 of 60 versus 46 of 60; P = 0.0001) and <z:mpath ids='MPATH_124'>infarct</z:mpath> size (21 +/- 2% versus 29 +/- 3%, P = 0.02) and improved cardiac output (12.4 +/- 0.6 versus 9.7 +/- 0.6 ml/min; P = 0.002) </plain></SENT>
<SENT sid="6" pm="."><plain>Liraglutide also modulated the expression and activity of cardioprotective genes in the mouse heart, including Akt, GSK3beta, PPARbeta-delta, Nrf-2, and HO-1 </plain></SENT>
<SENT sid="7" pm="."><plain>The effects of liraglutide on survival were independent of <z:hpo ids='HP_0001824'>weight loss</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Moreover, liraglutide conferred cardioprotection and survival advantages over <z:chebi fb="0" ids="6801">metformin</z:chebi>, despite equivalent glycemic control, in diabetic mice with experimental MI </plain></SENT>
<SENT sid="9" pm="."><plain>The cardioprotective effects of liraglutide remained detectable 4 days after cessation of therapy and may be partly direct, because liraglutide increased cyclic <z:chebi fb="47" ids="16027,28971">AMP</z:chebi> formation and reduced the extent of caspase-3 activation in cardiomyocytes in a GLP-1R-dependent manner in vitro </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: These findings demonstrate that GLP-1R activation engages prosurvival pathways in the <z:mpath ids='MPATH_458'>normal</z:mpath> and diabetic mouse heart, leading to improved outcomes and enhanced survival after MI in vivo </plain></SENT>
</text></document>